ZBTB16 and non-small cell lung carcinoma: Recent studies suggest that ZBTB16 is downregulated in non-small cell lung cancer (NSCLC) and is associated with poor prognosis (Otálora-Otálora et al., 2023), but its specific mechanism still needs further exploration.